Eckard Rehbinder – författare

No detailed description available for "Environmental Protection Policy".

The setting of limit values for environmental noxae is essentially based on measurements and data from single exposures. To an increasing degree, however, there are demands also to consider combined exposures. Hence, in this study, the necessity and feasability of environmental standards for combined exposures have been examined from the scientific, medical, economic, legal, sociological and philosophical/ethical perspective. Starting from effect mechanisms, criteria have been established which, in spite of the complexity of the issues, enable us to set limit values in order to achieve given environmental quality targets. This study endeavours to reveal and explain gaps in knowledge and to point to possible solutions from the scientific and medical point of view. The results should support efforts to shape a practical legal framework and viable economic procedures for environmental standards on combined exposures, taking into consideration the standards and perceptions existing in our communities.

Das k}rzlich verabschiedete Umwelthaftungsgesetz wirft eine Vielzahl von umweltrechtlichen und umwelt|konomischen Fragen auf, z.B. bez}glich der - rechts- und umweltpolitischen Zielsetzung des Umwelthaftungsgesetzes, - der Wirksamkeit des Umwelthaftungsgesetzesals Anreiz zur Schadensverh}tung, - der Anreizkompatibilit{t der obligatorischen Umwelthaftpflicht-Versicherung, - der Grenzen der Versicherbarkeit von Umweltrisiken, - der Besonderheiten im Falle des Mitverschuldens des Gesch{digten und bei Summations- und Distanzsch{den, - der M|glichkeiten von Fondsl|sungen, Umweltgenossenschaften oder anderen kollektiven Schadenstragungssystemen und - der Rolle des Haftungsrechts im Kanon umweltpolitischer Instrumente. Das vorliegende Buch beleuchtet diese Fragen in einem interdisziplin{ren Dialog von Juristen und \konomen, der im Rahmen des Kollegs "Umweltstaat" der Gottlieb Daimler- und Carl Benz-Stiftung in den Jahren 1989 bis 1991 stattgefunden hat. Es bietet einenumfassenden ]berblick }ber die Probleme und Perspektiven des Haftungsrechts als Instrument des "Umweltstaats".

Recent scientific advances have made it possible to produce biopharmaceuticals in genetically modified plants and animals, such as maize, tobacco, goats, and chickens. This new branch of biotechnology is termed pharming, composed of the terms pharmaceuticals and farming. Pharming constitutes an overlap of red and green biotechnology. It offers the prospect of a quicker, cheaper, and more flexible production of biopharmaceuticals compared with current production processes. This is a promising perspective in light of the rapidly growing market of biopharmaceuticals, although the economic competitiveness of pharming remains to be proven. Besides possible benefits for producers, patients and health care systems, pharming also raises a number of complex ecological, social, moral and legal questions that have as yet not been thoroughly discussed. The present book contains the findings of an interdisciplinary research project that has addressed a large range of questions associated with pharming: An analysis of the state-of-the-art of plant pharming and animal pharming technologies is followed by an assessment of environmental risks related to pharming and welfare risks for pharming animals. Public views and attitudes to pharming are investigated on the basis of a comprehensive survey in 15 countries. Moreover, ethical and legal questions, posed by present and foreseeable future practices of pharming, are analysed. The concluding chapter presents the authors’ main findings and recommendations, addressed to science, industry, politics and general public interested in the chances and risks of this upcoming field of biotechnology.

The setting of limit values for environmental noxae is essentially based on measurements and data from single exposures. To an increasing degree, however, there are demands also to consider combined exposures. Hence, in this study, the necessity and feasability of environmental standards for combined exposures have been examined from the scientific, medical, economic, legal, sociological and philosophical/ethical perspective. Starting from effect mechanisms, criteria have been established which, in spite of the complexity of the issues, enable us to set limit values in order to achieve given environmental quality targets. This study endeavours to reveal and explain gaps in knowledge and to point to possible solutions from the scientific and medical point of view. The results should support efforts to shape a practical legal framework and viable economic procedures for environmental standards on combined exposures, taking into consideration the standards and perceptions existing in our communities.

Recent scientific advances have made it possible to produce biopharmaceuticals in genetically modified plants and animals, such as maize, tobacco, goats, and chickens. This new branch of biotechnology is termed pharming, composed of the terms pharmaceuticals and farming. Pharming constitutes an overlap of red and green biotechnology. It offers the prospect of a quicker, cheaper, and more flexible production of biopharmaceuticals compared with current production processes. This is a promising perspective in light of the rapidly growing market of biopharmaceuticals, although the economic competitiveness of pharming remains to be proven. Besides possible benefits for producers, patients and health care systems, pharming also raises a number of complex ecological, social, moral and legal questions that have as yet not been thoroughly discussed. The present book contains the findings of an interdisciplinary research project that has addressed a large range of questions associated with pharming: An analysis of the state-of-the-art of plant pharming and animal pharming technologies is followed by an assessment of environmental risks related to pharming and welfare risks for pharming animals. Public views and attitudes to pharming are investigated on the basis of a comprehensive survey in 15 countries. Moreover, ethical and legal questions, posed by present and foreseeable future practices of pharming, are analysed. The concluding chapter presents the authors’ main findings and recommendations, addressed to science, industry, politics and general public interested in the chances and risks of this upcoming field of biotechnology.

Radioactive waste (above all highly radioactive wastes from nuclear installations) caused by research, medicine and technology must be disposed of safely. However both the strategies disputed for the disposal of radioactive waste as well as concrete proposals for choosing a location for final waste disposal are highly debatable. An appropriate disposal must conform to both complex, technical requirements and fulfill the radio-biological conditions to appropriately protect man and nature. Ethical, legal and social conditions must also be considered. An interdisciplinary team from various, relevant fields compiled the current status-quo and developed criteria and strategies, which on the one hand meet the requirements of optimal warning and prevention of risk for present and future generations, and additionally on the other hand meet the needs of what current society agrees what is expected to be allowed. This study can be understood as an advanced and continuing contribution to the corresponding scientific specialized debates, due to its interdisciplinary treatment. At the same time it serves as a fundamentally informing contribution to public and political debates, offering an easily comprehensible executive summary and precise content recommendations.